GlaxoSmithKline's Immutep-partnered midstage GI med culled in ulcerative colitis

It’s not been a great week for GlaxoSmithKline’s partnered R&D projects; after being forced to cull a major lung cancer trial with Merck KGaA, it’s now a case of déjà vu as it axes yet another experimental drug study.

This time it’s with Immutep, an Australian biotech it has long roots with, as the two have an R&D pact stretching all the way back to late 2010. That deal centered on IMP731, which works by depleting LAG-3 positive cells.